Extensive evidence has shown that platelets support tumor metastatic progression by inducing epithelial-mesenchymal transition of cancer cells and by shielding circulating tumor cells from immune-mediated elimination. Therefore, blocking platelet function represents a potential new avenue for therapy focused on eliminating metastasis. Here we show that liposomal nanoparticles bearing the tumor-homing pentapeptide CREKA (Cys-Arg-Glu-Lys-Ala) can deliver a platelet inhibitor, ticagrelor, into tumor tissues to specifically inhibit tumor-associated platelets. The drug-loaded nanoparticles (CREKA-Lipo-T) efficiently blocked the platelet-induced acquisition of an invasive phenotype by tumor cells and inhibited platelet-tumor cell interaction in vitro. Intravenously administered CREKA-Lipo-T effectively targeted tumors within 24 h, and inhibited tumor metastasis without overt side effects. Thus, the CREKA-Lipo formulation provides a simple strategy for the efficient delivery of anti-metastatic drugs and shows considerable promise as a platform for novel cancer therapeutics.
Inhibition of platelet function using liposomal nanoparticles blocks tumor metastasis
Yinlong Zhang,Jingyan Wei,Shaoli Liu,Jing Wang,Xuexiang Han,Hao Qin,J. Lang,Keman Cheng,Yiye Li,Yingqiu Qi,Greg J. Anderson,S. Sukumar,Suping Li,Guangjun Nie
Published 2017 in Theranostics
ABSTRACT
PUBLICATION RECORD
- Publication year
2017
- Venue
Theranostics
- Publication date
2017-02-26
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-27 of 27 references · Page 1 of 1
CITED BY
Showing 1-83 of 83 citing papers · Page 1 of 1